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Mnt modulates Myc-driven lymphomagenesis
Kirsteen J Campbell1,4,5, Cassandra J Vandenberg1,2,5, Natasha S Anstee1,2, Peter J Hurlin3 and Suzanne Cory*,1,2
The transcriptional represser Mnt is a functional antagonist of the proto-oncoprotein Myc. Both Mnt and Myc utilise Max as an
obligate partner for DNA binding, and Myc/Max and Mnt/Max complexes compete for occupancy at E-box DNA sequences in
promoter regions. We have previously shown in transgenic mouse models that the phenotype and kinetics of onset of
haemopoietic tumours varies with the level of Myc expression. We reasoned that a decrease in the level of Mnt would increase the
functional level of Myc and accelerate Myc-driven tumorigenesis. We tested the impact of reduced Mnt in three models of myc
transgenic mice and in p53+/− mice. To our surprise,mnt heterozygosity actually slowed Myc-driven tumorigenesis in vavP-MYC10
and Eμ-myc mice, suggesting that Mnt facilitates Myc-driven oncogenesis. To explore the underlying cause of the delay in tumour
development, we enumerated Myc-driven cell populations in healthy young vavP-MYC10 and Eμ-myc mice, expecting that the
reduced rate of leukaemogenesis in mnt heterozygous mice would be reflected in a reduced number of preleukaemic cells, due
to increased apoptosis or reduced proliferation or both. However, no differences were apparent. Furthermore, when mnt+/+ and
mnt+/− pre-B cells from healthy young Eμ-myc mice were compared in vitro, no differences were seen in their sensitivity to
apoptosis or in cell size or cell cycling. Moreover, the frequencies of apoptotic, senescent and proliferating cells were comparable
in vivo in mnt+/− and mnt+/+ Eμ-myc lymphomas. Thus, although mnt heterozygosity clearly slowed lymphomagenesis in
vavP-MYC10 and Eμ-myc mice, the change(s) in cellular properties responsible for this effect remain to be identified.
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c-Myc (hereafter Myc) is a basic helix–loop–helix–leucine
zipper (bHLHZip) transcription factor that regulates a multi-
tude of cellular processes, including cell growth, proliferation,
metabolism, DNA damage response, malignant transfor-
mation and apoptosis.7,10,14,16,20,48,49 In normal cells, Myc
expression is tightly regulated during the cell cycle but in many
cancers control is abrogated, due to chromosomal transloca-
tion, mutation or amplification of themyc gene, or as a result of
mutations affecting upstream regulatory pathways. Whether
Myc targets specific groups of genes or serves as a global
amplifier of the transcriptional programme inherent to indivi-
dual cell types remains the subject of vigorous debate and
experimentation.27,29,34 Irrespective, the level of Myc expres-
sion critically influences cellular outcome.33
Myc heterodimerises with a ubiquitous bHLHZip protein,
Max, and binds the E-box CACGTG to activate gene trans-
cription.5 Max also binds transcriptional repressors containing
Myc-related bHLHZ domains, such as the Mxd proteins and
Mnt.10,22,55 Since these repressors compete with Myc for
available Max and also bind E boxes, they function as Myc
antagonists. Hence their loss would be predicted to mimic
Myc overexpression. Deletion of Mxd proteins in mice did
not produce a phenotype resembling Myc overexpression,
perhaps because expression of Mxd proteins is primarily
confined to differentiated cells.22 In contrast, loss of Mnt,
which is expressed in both proliferating and differentiating cells
in all tissues tested,24 resulted in accelerated proliferation,
susceptibility to transformation by oncogenic Ras and
sensitivity to apoptosis, all characteristics of Myc over-
expression.22,25,35 Surprisingly, these effects of Mnt knock-
down were observed also in cells lacking Myc, leading to
the suggestion that Myc functions as a Mnt antagonist,
relieving Mnt-mediated repression, rather than by transcrip-
tional activation as is widely believed.35 However, irrespective
of whether Mnt controls Myc or Myc controls Mnt, the level of
Mnt would be expected to influence the oncogenic potential
of Myc.
Mnt can serve as a tumour suppressor, as tissue-specific
deletion of Mnt in mice resulted in mammary adenocarcino-
mas and T-cell lymphomas.8,25,47 Conversely, Mnt over-
expression mimicked Myc knockout, producing growth
defects and embryonic lethality25 as well as reducing cell
cycle entry and proliferation of MEFs in vitro.53 In further
support of a tumour suppressor role, deletion of the region
encompassing the MNT locus has been reported in human
chronic lymphocytic leukaemia12 and in Sezary syndrome,52
a cutaneous T-cell lymphoma/leukaemia. A recent study has
suggested that the dominant role of Mnt, at least in proli-
ferating T cells, is suppression of Myc-driven apoptosis.30
Transgenic mice have been a powerful tool for analyzing the
role of Myc in malignancy.32 Our Eμ-myc transgenic mice,1,21
which model the 8;14 translocation found in Burkitt’s B
lymphomas, have provided many insights into Myc-driven
lymphomagenesis. The overexpression of Myc produces a
polyclonal increase in pre-B cells in young mice, accom-
panied by reduced differentiation to mature B cells.28
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However, Myc overexpression also enhances susceptibility to
apoptosis,3,17,45 which restrains progression of preleukaemic
cells to malignancy. Consequently, anti-apoptotic mutations
synergise with myc to promote malignant transforma-
tion4,13,15,40,44,51 and the pre-B and B lymphomas that
eventually arise in Eμ-myc mice often harbour mutations that
mutate p53 or its upstream regulators,15 as do Burkitt
lymphomas.18,19,31,54
More recently we developed several transgenic lines that
express Myc via haemopoietic-specific regulatory elements
from the vav gene.42,43 The tumour phenotype of the
vavP-MYC mice varied between lines, depending on the level
of Myc achieved: high expression resulted in rapid-onset T-cell
lymphomas whereas low expression resulted in late-onset
myeloid tumours and intermediate levels produced both
tumour types.
Reasoning that the level of Mnt would affect Myc activity, in
this study we have investigated the impact of mnt hetero-
zygosity on Myc-driven tumorigenesis, using both vavP-MYC
and Eμ-mycmousemodels.We also investigated whethermnt
heterozygosity influenced tumorigenesis in p53+/− mice.
Results
Mnt heterozygosity confers reduced Mnt expression. We
first ascertained how mnt heterozygosity impacted expres-
sion of Mnt and Myc. Western blot analysis verified that the
level of Mnt protein was lower inmnt+/− compared withmnt+/+
thymocytes, both on the WT and vavP-MYC17 transgenic
background (Figure 1a) and in pre-B cells from WT and
Eμ-myc mice (Figures 1b and c) and the level of transgenic
Myc was unaltered. Quantitative PCR analysis confirmed that
mnt RNA was ~2-fold lower in mnt+/− Eμ-myc versus mnt+/+
Eμ-myc pre-B cells (Figure 1d).
Decreased Mnt does not accelerate tumorigenesis in
vavP-MYC transgenic mice. To study the impact of mnt
heterozygosity on Myc-driven lymphomagenesis, we turned
first to vavP-MYC10 mice because the level of MYC protein
expressed in this line represents a critical functional thresh-
old: When expression is increased ~2-fold (by generating
mice homozygous for the transgenic locus; hereafter vavP-
MYC10hom mice), the mice develop predominantly T lympho-
mas rather than the mixture of T lymphomas and myeloid
tumours found in mice heterozygous for the transgene.43 We
reasoned that lowering the level of Mnt in vavP-MYC10het
mice would increase the level of MYC/Max heterodimers
and drive the phenotype towards that seen in vavP-
MYC10hom mice; viz more rapid tumour onset, and primarily
T lymphomas rather than a mixture of T and myeloid
tumours.43
Cohorts of mnt+/+vavP-MYC10 (n=54) and mnt+/−vavP-
MYC10 (n=50) transgenic mice) were monitored for tumour
onset. Surprisingly, the outcome was the opposite from that
predicted: Mnt heterozygosity (black line) resulted in slower
tumour-associated morbidity (Po0.001) (Figure 2a, left panel)
and, with the exception of one pre-B lymphoma, all tumours
were myeloid (Figure 2a, right panel).
In MYC10hom mice expressing higher MYC levels, mnt
heterozygosity also retarded morbidity, although not reaching
statistical significance (Figure 2b, left panel). Furthermore, the
frequency of T lymphomas was reduced (77% inmnt+/−vavP-
MYC10hom mice versus 92% in mnt+/+vavP-MYC10hom mice)
and morbidity due to myeloid tumours increased (23% versus
8%) (Figure 2b, right panel). Taken together, these results
suggested that Mnt heterozygosity reduces the risk of Myc-
driven T lymphomagenesis in vavP-MYC10 transgenic mice.
Next, the impact of mnt heterozygosity was tested in vavP-
MYC17 mice (Figure 2c). The level of vavP-MYC transgene
expression is highest in this line and lymphomagenesis much
faster.43 Therefore it was not particularly surprising to find that
mnt heterozygosity had no impact on the kinetics of morbidity
(Figure 2c, left panel). Interestingly, however, while all mice still
succumbed to T lymphoma, there appeared to be a shift in
tumour phenotype, a decrease in the frequency of CD4 SP
(CD4+CD8−) T lymphomas (50% down to 22%) and
an increase in those having a mixed (DP plus SP or DN)
phenotype (4.5% up to 39%), suggestive of an impact on
T lymphoid differentiation (Figure 2c, right panel).
Decreased Mnt retards tumorigenesis in Eμ-myc trans-
genic mice. To ascertain whether mnt heterozygosity also
impaired B lymphoid tumour development, we crossed
mnt+/− mice with Eμ-myc mice, in which transgene expres-
sion is largely restricted to the B lymphoid lineage. Once
again, mnt heterozygosity slowed rather than accelerated
tumour development, the median onset being 197 days for
mnt+/− Eμ-myc mice versus 118 days for mnt+/+ Eμ-myc
littermates (P= 0.004) (Figure 3a, left panel). There was no
detectable change in tumour phenotype, both genotypes
developing pre-B and B-cell lymphomas at about the same
relative frequency (Figure 3a, right panel). Furthermore, there
was no significant difference in the severity of disease, as
reflected in the spleen weight or peripheral leucocyte count of
moribund mice (Figure 3b).
Impact of Mnt heterozygosity in p53+/− mice. We also
tested the impact of mnt heterozygosity in p53-deficient mice,
in which Myc can have a major impact on tumorigenesis.
Lymphomas develop rapidly and at high frequency in p53− /−
mice but are rare in p53+/− mice, which develop a range of
other cancers, albeit after a long latency.11,26,37 We had
reasoned that if decreased Mnt increased the level of
functional Myc in lymphoid cells of p53 heterozygotes, then
the frequency of lymphomas would increase and the latency
shorten, as it does if an Eμ-myc transgene is introduced into
p53+/− mice.6,23,40 Once again, however, mnt heterozygosity
tended to retard tumour development, although not reaching
statistical significance (Figure 4, left panel). The frequency of
lymphomas versus other tumour types was not altered
(Figure 4, right panel).
Does Mnt heterozygosity perturb preleukaemic cell
populations in vivo?. In contrast to earlier studies,8,25,47
these results had provided no evidence for a tumour
suppressor role for Mnt in any of the mouse models tested.
Indeed, they suggested instead that Mnt facilitates Myc’s
oncogenic role.
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To gauge any impact of mnt heterozygosity on the
premalignant Myc phenotype, we analysed haemopoietic
tissues of healthy young mice, prior to tumour onset. Young
Eμ-myc mice harbour excessive numbers of immature B
lymphoid cells, accompanied by reduced numbers of mature
B cells.28 No major differences were apparent between
6-week-old mnt+/− and mnt+/+ Eμ-myc mice (Figure 5 and
Supplementary Table S1). In both genotypes, the bone
marrow, spleen and lymph nodes contained abnormally
high numbers of pre-B (B220+sIg−) and immature B
(B220+sIgM+sIgD−) cells, and diminished numbers of mature
B cells (B220+sIgM+sIgD+). As expected,28 homoeostasis had
improved by 12 weeks (Supplementary Table S2) but there
were no significant differences in B lymphoid populations in
mnt+/− Eμ-myc and mnt+/+ Eμ-myc mice, in any tissue, at
either time point.
vavP-MYC10 mice were analysed at 9–10 weeks of age
(Supplementary Table S3). Once again, no statistically
significant differences were found between mnt+/+ and
mnt+/− transgenic mice in the populations expressing the
transgene, either lymphoid (B or T) or myeloid.
Due to the early onset of malignancy in the vavP-MYC17
line, these mice were analysed at 2 weeks. Interestingly,
the transient B lymphoid hyperplasia found in these mice42
was significantly diminished in mnt+/− mice compared with
mnt+/+vavP-MYC17 littermates, as was the (modest) eleva-
tion in peripheral T cells (Supplementary Table S4). Thus,
reduced expression of Mnt correlatedwith reducedMyc-driven
expansion of B- and T-cell numbers in healthy young vavP-
MYC17 mice.
In summary, analyses of preleukaemic populations in the
vavP-MYC10 and Eμ-myc mice yielded little insight into why
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Figure 1 Expression analysis of mnt+/+ and mnt+/− lymphoid cells from WT and myc transgenic mice. (a) Mnt and transgenic MYC protein expression in thymocytes
from mnt+/+ and mnt+/− WT and vavP-MYC17 mice. Western blots of lysates of thymocytes from four-week-old mice of the indicated genotypes, probed with antibodies
specific for Myc, Mnt, Max and β-actin (see Materials and Methods). Each lane represents an individual mouse. Comparable results were obtained for thymocytes from
mnt+/+ and mnt+/− vavP-MYC10 mice. (b) Mnt and transgenic Myc protein expression in pre-B cells from mnt+/+ and mnt+/− Eμ-myc mice. Western blot analysis of
pre-B cells (B220+sIg−) sorted by flow cytometry from bone marrow of 4-week-old mice of indicated genotypes. Each lane represents an individual mouse and MWs (kD) of
markers run in parallel are indicated. Endogenous Myc was not detectable in WT control cells. (c) Quantification of Mnt and Myc protein expression in mnt+/+ and mnt+/−
WT and Eμ-myc mice. The blot shown in (b) and two additional blots using independent samples were quantified using ChemiDoc and Image Lab software (Bio-Rad), with
normalisation to actin expression. Expression is relative to the first mnt+/+ Eμ-myc sample on each blot. (d) Quantitative PCR analysis ofmyc andmnt RNA in pre-B cells isolated
using magnetic beads coated with CD19 antibody from the bone marrow of 4-week-old mice of the indicated genotypes (n= 2–15). Data are normalised to myc expression
in mnt+/+ Eμ-myc mice
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mnt heterozygosity had retarded Myc-driven tumorigenesis in
these mice. While changes were observed in young vavP-
MYC17 mice, these changes did not impact on the kinetics of
morbidity and the unfortunate loss of this line has prevented
any further analysis.
Assessing impact ofmnt heterozygosity on cell function.
To look more closely at which Myc-induced cellular pheno-
types might have been altered by reduction in Mnt, we
decided to focus our attention on the Eμ-myc model. Charac-
teristics previously reported for cells overexpressing Myc
include increased cell size, increased proportion of cells in
the S phase of the cell cycle and increased sensitivity to
apoptosis,3,17,28,41 many of which have also been reported for
cells lacking Mnt.25,30,35
In order to avoid the complication of additional oncogenic
changes, we analysed preleukaemic B lymphoid cell popula-
tions from healthy young (4- to 6-week-old) Eμ-mycmice. Cell
size was assessed by determining mean forward light scatter
by flow cytometry (Figure 6a). Representative size profiles are
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Figure 2 Impact of mnt heterozygosity on tumorigenesis in vavP-MYC mice. (a) Tumorigenesis in vavP-MYC10 mice. Left panel: Kaplan–Meier survival curve showing
delayed morbidity in mnt+/− vavP-MYC10 mice (black line, n= 50, median survival 349 days) versus mnt+/+vavP-MYC10 mice (grey line, n= 54, median survival 276 days);
Po0.001, Log-rank (Mantel–Cox) test. Right panel: Incidence of different tumour types, identified by immunostaining and flow cytometry (see Materials and Methods). For
mnt+/+vavP-MYC10 mice, 13% of tumours were T lymphoid (CD4+CD8+) and 87% were myeloid (Mac1+); for mnt+/− vavP-MYC10mice, 3% of tumours were pre-B cell (CD19+
B220+ IgM−IgD−) and 97% were myeloid (Mac1+). (b) Tumorigenesis in vavP-MYC10hom mice. Left panel: Kaplan–Meier survival curve for mnt+/+vavP-MYC10hommice (grey
line, n= 14, median 116 days) and mnt+/− vavP-MYC10hommice (black line n= 25, median 120 days). Right panel: For mnt+/+vavP-MYC10hom mice, 92% of tumours were T
lymphoid (CD4+CD8+) and 8% were myeloid (Mac1+); formnt+/− vavP-MYC10hom mice, 77% of tumours were T lymphoid (CD4+CD8+) and 23% were myeloid. (c) Tumorigenesis
in vavP-MYC17 mice. Left panel: Kaplan–Meier survival curve showing similar survival ofmnt+/+vavP-MYC17 mice (grey line, n= 33; median 7 weeks) andmnt+/− vavP-MYC17
mice (black line, n= 34; median 7 weeks). Right panel: All tumours were T lymphoid. For mnt+/+ vavP-MYC17 mice, 41% were DP (CD4+ CD8+); 50% were CD4 SP
(CD4+CD8−); 4.5% were DN (CD4−CD8−); 4.5% were mixed (DP and SP or DN). For mnt+/− vavP-MYC17 mice, 35% were DP; 22% were CD4 SP; 4% were CD8 SP
(CD4−CD8+); 39% were mixed
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shown in the left panel and the adjacent panels summarise the
mean forward light scatter of pre-B (B220+sIg−), immature
B (B220+IgM+IgD−) and mature B (B220+IgM+IgD+) cells,
expressed relative to that of non-trangenic cells analysed
contemporaneously. As expected, 28 the mean size of each B
lymphoid cell type was greater for myc transgenic than non-
transgenic cells. Mnt heterozygosity did not affect the size
profile of non-transgenic or transgenic cells of any major
B lymphoid type from lymph nodes (right panel) or bone
marrow or peripheral blood (not shown), with the exception
of pre-B cells from the spleen of mnt+/− Eμ-myc mice, which
were somewhat larger than those in mnt+/+ Eμ-myc mice
(middle panel).
Cell cycle analysis of preleukaemic pre-B cells from bone
marrow was performed by flow cytometry. As reported
previously,28 the proportion of cells in the S and G2 phases
was greater for cells from Eμ-myc than non-transgenic mice.
However, mnt heterozygosity had no significant impact on the
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Figure 3 Impact ofmnt heterozygosity on lymphomagenesis in Eμ-mycmice. (a) Left panel: Kaplan–Meier survival curve showing delayed morbidity from tumours inmnt+/−
Eμ-myc mice (black line, n= 43, median survival 28 weeks) compared with mnt+/+ Eμ-myc mice (grey line, n= 31, median survival 17 weeks). P= 0.0042. By 12 months, all
mnt+/+ Eμ-myc mice had succumbed to tumours, whereas 29% of mnt+/− Eμ-myc mice were still alive. Right panel: mnt heterozygosity had no impact on lymphoma phenotype
in Eμ-myc mice. Of 33 tumours from mnt+/+ Eμ-myc mice analysed, 45.5% were pre-B cell, 51.5% were B cell and 3% were mixed pre-B/B-cell tumours. Similarly, of 27 tumours
from mnt+/− Eμ-myc mice, 52% were pre-B cell and 48% were B-cell tumours. (b) Tumour burden of moribund mice. Left panel: Spleen weight of moribund mnt+/+ Eμ-myc
(n= 28) and mnt+/− Eμ-myc mice (n= 43) mice. Right panel: white blood cell count of moribund mnt+/+ Eμ-myc (n= 14) and mnt+/− Eμ-myc (n= 22) mice. Bars represent
mean ± S.E.M. No significant differences were observed
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Figure 4 Impact of mnt heterozygosity in p53 heterozygous mice. Left panel: Kaplan–Meier survival curve for mnt+/+ p53+/− mice (grey line, n= 24, median survival
60 weeks) and mnt +/− p53+/− mice (black line, n= 25, median survival 75 weeks). Survival curves for p53+/− mnt+/+ and p53+/− mnt+/− are not significantly different. Right
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cycling of either transgenic or non-transgenic pre-B cells
(Figure 6b). Moreover, it did not affect the level of transcripts
from the cdk4 and odc genes, both of which are targeted by
Myc during cell cycling (Figure 6c).2,20,25
Sorted pre-B cells were cultured in conventional medium for
3 days to ascertain their susceptibility to apoptosis (Figure 6d).
As reported previously,45 the Eμ-myc cells died at a faster rate
than their non-transgenic counterparts, but mnt heterozygo-
sity had only marginal impact. Similarly, when IL-7 was
removed from IL-7-supported cultures of pre-B cells, mnt
heterozygosity had no significant impact (Figure 6e).
Impact of mnt heterozygosity on Eμ-myc lymphoma
cells. Having failed to observe any changes in the pre-
leukaemic cell populations that might account for the slower
onset of tumour-associated morbidity, we decided to assess
Eμ-myc lymphomas to ascertain whether reduced Mnt had
increased the probability of malignant Myc-driven cells
undergoing cell death in vivo or reduced their proliferation
rate. Tumour sections were stained for β-galactosidase
activity; cleaved caspase-3 or Ki-67 and scanned digitally to
quantify positive cells. No significant differences were
detected between mnt+/+ and mnt +/− Eμ-myc lymphomas in
the frequency of senescent (β-galactosidase-positive) or apo-
ptotic (cleaved caspase-3-positive) cells (Figures 7a and b).
Neither was there any difference in proliferation, as judged by
quantitation of Ki-67 staining (Figure 7c).
Discussion
The bHLHZip protein Myc activates transcription of a diverse
array of genes, thereby coordinating cellular proliferation in
response to cytokines, mitogens and nutrients. In normal cells,
Myc is tightly regulated at transcriptional, post-transcriptional
and post-translational levels, preventing inappropriate expan-
sion of cell numbers and thereby reducing the risk of malig-
nancy. As a further safeguard, Myc increases the propensity of
cells to undergo apoptosis when cytokines and nutrients
become limiting.3,17,41 Thus, somewhat paradoxically, Myc
has properties of both a proto-oncoprotein and a tumour
suppressor protein. The level of Myc expression can influence
the balance between proliferation and apoptosis, because
apoptosis was reported to be robust at high levels of Myc
but minimal when Myc levels are low, perhaps reflecting
differential affinities for target genes.33
The transcriptional repressor Mnt, also a bHLHZip protein,
is a functional antagonist of Myc. Mnt competes with Myc for
dimerisation with their mutual obligate partner Max and for
binding at E-box sites in an overlapping set of target genes.22
Mnt overexpression can suppress Myc-dependent cell
proliferation24 and tissue-specific loss of Mnt in mice resulted
in mammary adenocarcinomas and T-cell lymphomas.8,25,47
Thus Mnt has been regarded as a tumour suppressor.
In this study, we set out to determine the impact of reduced
Mnt levels on Myc-driven tumorigenesis. VavP-MYC10 mice
were selected for the initial study because they are a useful
barometer of MYC leukaemogenic function: Mice bearing one
transgenic MYC allele develop both early onset
T lymphomas and late myeloid tumours, and homozygosity
greatly increases the frequency of T lymphomas and
accelerates morbidity.43 We thought that reducing Mnt levels
would be comparable to increasing Myc and hence expected
to see accelerated tumorigenesis and increased T lymphoma
frequency in mice heterozygous for vavP-MYC10 and hetero-
zygous for mnt. In fact, the opposite occurred: mnt+/− vavP-
MYC10 mice developed fewer T lymphomas and morbidity
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Figure 5 Impact of mnt heterozygosity on pre-tumour phenotype of Eμ-myc mice. Enumeration of cell populations in 6-week-old mnt+/+ (white; n= 5–6), mnt+/− (diagonal
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was slower (Figure 2a). These results suggested that mnt
heterozygosity had reduced susceptibility to Myc-driven
T lymphomagenesis. Tumorigenesis was not significantly
retarded in mice homozygous for the vavP-MYC10 transgene
or in another T lymphoma-susceptible line (vavP-MYC17),
possibly because Mnt heterozygosity is insufficient to counter
the higher levels of Myc in these strains.
When the experiment was repeated with Eμ-myc mice,
in which transgene expression is largely restricted to the
B lymphoid lineage, mnt heterozygosity again resulted in
slower tumour onset. Thus, reducing Mnt by 50% can impede
both B and T lymphomagenesis in two independent transgenic
myc models.
Similar findings have been made recently using a different
model: T-cell specific acute deletion of mnt and a ROSA-26
locus-driven mycT58A mutant transgene.30 While mycT58A
mice succumbed to thymic lymphomas with a median survival
of 220 days, mnt deletion resulted in a median survival of
355 days and none of the mnt-/− mycT58A mice developed
thymic lymphoma. Link et al. also showed that Mnt-deficient
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mnt+/+ and mnt+/− WT and Eμ-myc mice. Cells were immunostained then gated for pre-B cells (B220+IgM−IgD−), immature B cells (B220+IgM+IgD−) and mature B cells
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mnt+/+ (red dashed line), mnt+/− (green dashed line), Eμ-myc (orange solid line) and two mnt+/− Eμ-myc (blue solid lines) 6-week-old mice. Right panels show B lymphoid cell
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(black; n= 3–5) mice. Bars represent mean± S.E.M. Statistical significance is shown for only WT vs mnt+/− and Eμ-myc vs mnt+/− Eμ-myc; *Po0.05 as calculated by
Student’s t-test. (b and c) Mnt heterozygosity has no discernible impact on cycling of pre-B cells. (b) Proportion of pre-B cells in the indicated phases of the cell cycle, determined
using Nicoletti stain, flow cytometry and Dean/Jett/Fox modelling using FlowJo software (see Materials and Methods). Pre-B cells were isolated from bone marrow of 4-week-old
mice of the indicated genotypes using magnetic beads coated with CD19 antibody. (c) Quantification of cdk4 and odc transcripts in sorted pre-B cells by q-PCR analysis.
Expression is indicated relative to mnt+/+ Eμ-myc cells. (d and e) Mnt heterozygosity has no discernible impact on apoptosis of pre-B cells in vitro. (d) Pre-malignant pre-B cells
isolated from the bone marrow of 4-week-old mice using magnetic beads coated with CD19 antibody were cultured in conventional medium without additional cytokines and
viability determined at the indicated time points by flow cytometry (see Materials and Methods). For each genotype, viability is expressed relative to that at t= 0. Similar results
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thymocytes and concanavalin A-activated splenic T cells were
more susceptible to apoptosis in vitro and concluded that the
dominant physiological role of Mnt is suppression of apopto-
sis. The inference is that, by counteracting Myc’s capacity to
promote apoptosis, Mnt facilitates Myc’s oncogenic drive.
We considered that diminished suppression of apoptosis
was also a likely explanation for why mnt heterozygosity
retards lymphomagenesis in our vavP-MYC10 and Eμ-myc
mice. Nevertheless, wewere unable to provide direct evidence
for this. Increased susceptibility to apoptosis might have been
expected to reduce the number of Myc-driven preleukaemic
cells. However, mnt heterozygosity provoked no diminution
of pre-B-cell numbers in healthy young Eμ-myc mice, nor
of lymphoid (B or T) or myeloid populations in vavP-MYC10
mice (Supplementary Tables S1), although the transient pre-
B-cell population in neonatal mnt+/− vavP-MYC17 mice was
significantly reduced (Supplementary Table S4). Furthermore,
when we cultured preleukaemic Eμ-myc pre-B cells, we found
no evidence that mnt heterozygosity increased their suscept-
ibility to apoptosis (Figures 6d and e).
Reasoning that mnt heterozygosity might be insufficient
to enhance susceptibility to Myc-driven apoptosis in vitro
but might have conferred increased susceptibility in vivo
to particular physiological signals or to other oncogenic
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Figure 7 Impact of mnt heterozygosity on Eμ-myc lymphoma cells. (a) mnt heterozygosity has no impact on senescence. Sections of lymph node lymphomas of mnt+/+
Eμ-myc (n= 12) andmnt+/− Eμ-myc (n= 7) mice were stained for β-galactosidase activity, counterstained with nuclear fast red (see Materials and Methods) and scanned on an
Aperio Digital Pathology Slide Scanner. β-Galactosidase-positive cells in extracted images were quantified using Fiji software. Data shown are mean±S.E.M. (b) mnt
heterozygosity does not impact upon apoptosis. Sections of lymphomas in lymph node and/or spleen of mnt+/+ Eμ-myc (n= 10) and mnt+/− Eμ-myc mice (n= 5) were stained
using an antibody specific for cleaved caspase-3 followed by a haematoxylin counterstain (see Materials and Methods). Cells positive for cleaved caspase-3 were quantified as in
(a) above. Data shown are mean± S.E.M. (c) Proliferation in Eμ-myc lymphomas is not altered by mnt heterozygosity. Sections of lymphomas in lymph node and/or spleen
of mnt+/+ Eμ-myc (n= 11) and mnt+/− Eμ-myc mice (n= 4) were stained for Ki-67 with haematoxylin counterstain. The Ki-67 positive area was quantified as in (a) above.
Data shown are mean±S.E.M.
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mutations, we quantitated cell death in sections of mnt+/+
versus mnt+/− Eμ-myc lymphomas. No significant differences
were found in the frequency of either apoptotic or senescent
cells (Figure 7). Furthermore, the reduced level of Mnt did
not diminish the proliferation of the tumour cells, as judged by
Ki-67 staining.
Although we have been unable to pinpoint the change(s)
responsible for the slower onset of morbidity in ourmnt+/− myc
transgenic mice, our study provides evidence that Mnt
facilitates Myc-driven tumorigenesis.55 Given the plethora of
genes regulated by opposing Myc/Max and Mnt/Max hetero-
dimers, functions other than enhanced apoptosis may con-
tribute. We are currently undertaking conditional (lymphoid-
specific) homozygous deletion of mnt in Eμ-myc and vavP-
MYC10 mice to further explore role of Mnt in apoptosis and
leukaemogenesis.
Materials and Methods
Mice. The vavP-MYC mice (which express human MYC cDNA42,43), Eμ-myc mice
(which express mouse myc cDNA21) and p53-deficient mice26 used in this study
were all on a C57BL/6 background and bred at the Walter and Eliza Hall Institute
(WEHI) in accordance with the WEHI animal ethics committee regulations. The
mnt+/− mice, originally on a 129/S6 background,46 were backcrossed to C57BL/6
mice for several generations prior to being sent to WEHI, where backcrossing to
C57BL/6 was continued. All mnt+/− mice used in this study had been backcrossed
for49 generations. The rapid T lymphoma onset in the vavP-MYC17 line made it
difficult to maintain a breeding colony,43 so cryopreserved sperm from vavP-MYC17
mice was used to fertilise oocytes from super-ovulated mnt+/− females (67
offspring) and vavP-MYC17 mnt+/− sperm was then collected and used to fertilise
oocytes from super-ovulated wild-type females (132 offspring). Moribund mice were
autopsied and organs collected for histology and immunophenotyping.
Antibodies. Western blots, prepared by standard procedures, were probed
using the following antibodies: c-Myc (N-262), Max (C-17) and Mnt (M-132) all from
Santa Cruz Biotechnology (Dallas, TX, USA), or c-Myc (D84C12) from Cell
Signaling Technology (Danvers, MA, USA) and Mnt (A303-626A) from Bethyl
Laboratories (Montgomery, TX, USA) and β-actin (AC-74, Sigma-Aldrich, St. Louis,
MO, USA). Blots in Figure 1b were imaged on a ChemiDoc Touch (Bio-Rad,
Hercules, CA, USA) and analysed using Image Lab software (Bio-Rad). Monoclonal
antibodies used for flow cytometry, produced and labelled with FITC, PE or APC in
house, included the following: RB6-8C5, anti-Gr1; MI/70, anti-Mac1; YTA3.2.1, anti-
CD4; 53.6.7.2, anti-CD8; Ter119, anti-erythroid marker; ID3, anti-CD19; RA3-6B2,
anti-CD45R-B220; 5.1, anti-IgM; 11-26C, anti-IgD; 145-2C11, anti-CD3; E13.161.7,
anti-Sca-1; 57, anti-CD43; T329.1, anti-Thy1; A20.1 anti-Ly5.1.
Cell phenotype analysis. An ADVIA haematology analyser (Bayer,
Leverkusen, Germany) or flow cytometer (LSR1; Becton Dickinson, Franklin Lakes,
NJ, USA) was used to analyse peripheral blood following treatment with a buffer
containing 0.168 M ammonium chloride to deplete red blood cells. Single-cell
suspensions were prepared from bone marrow (one femur), thymus, lymph nodes
(axillary, brachial, inguinal) and spleen. Viable cells were counted using a
haemocytometer and trypan blue exclusion or enumerated on a CASY Counter
(Scharfe Roche, Penzberg, Germany). Cell immunophenotype was determined by
staining with surface marker-specific antibodies followed by flow cytometry analysis.
Stained single-cell suspensions were sorted using a MoFlo (Cytomation, Fort
Collins, CO, USA) high speed sorter. Cell viability was determined by flow cytometry
following staining with propidium iodide and annexin V-FITC. Statistical significance
was determined using the Student’s t-test (two-tailed, assuming equal variance).
Cell cycle analysis. Pre-B cells were isolated from bone marrow using MACS
columns and CD19 beads (Miltenyi, Bergisch Gladbach, Germany), resuspended in
0.1% sodium citrate, 0.1% Triton X and 50 μg/ml propidium iodide (Nicoletti stain)38
and incubated on ice in the dark for 1 h prior to FACS analysis. Cell cycle profiles
were characterised using FlowJo software (Tree Star, Ashland, OR, USA).
Cell survival assays. Pre-B cells were isolated by magnetic purification using
CD19 MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) and MS
columns (Miltenyi Biotech) according to the manufacturer’s protocols. Cells were
cultured at 0.2–0.5 × 106 cells/ml in high-glucose Dulbecco’s modified Eagle’s
medium supplemented with 10% foetal calf serum (Sigma-Aldrich), 50 μM 2-
mercaptoethanol (2-ME; Sigma-Aldrich, St Louis, MO, USA) and 100 μM
asparagine (Sigma-Aldrich) without additional cytokines. Cell viability was
determined by staining with FITC-conjugated annexin V and propidium iodide
followed by flow cytometry. IL-7 cytokine withdrawal assay was performed as
published.50
Histology. For cleaved caspase-3 or Ki-67 immunohistochemistry (IHC),
spleens and lymph nodes from lymphoma-bearing mice were fixed in 10% formalin
and then embedded in paraffin. Sections were stained for cleaved caspase-3 using
the SignalStain Apoptosis (Cleaved Caspase-3) IHC Detection Kit (Cell Signaling
Technology) according to the manufacturer’s protocol and counterstained
with haematoxylin. Ki-67 IHC was performed using D3B5 Rabbit mAb (Cell
Signaling Technology). To assess senescence, we followed the protocol of Post
et al.36 Briefly, lymph nodes from lymphoma-bearing mice were fixed for 2 h in 4%
paraformaldehyde, and then incubated for at least 6 h in 10% sucrose/Hanks’
Balanced Salt Solution (HBSS), followed by 15% sucrose/HBSS, then 20% sucrose/
HBSS, before snap freezing in Tissue-Tek O.C.T. Compound (Sakura Finetek,
Torrance, CA, USA). Cryosections were stained for SA-β-galactosidase as
previously described,9 and counterstained with nuclear fast red. Complete slides
were scanned on an Aperio Digital Pathology Slide Scanner and regions to be
analysed were extracted using ImageScope software (Leica Biosystems, Wetzlar,
Germany). Cleaved caspase-3 or β-galactosidase-positive cells were quantified
using Fiji software (ImageJ, NIH, Bethesda, MD, USA).39
PCR analysis. Lymphocyte populations were purified as described above. Total
RNA was isolated using RNeasy mini kit (Qiagen, Hilden, Germany). In total, 0.2 μg
of RNA was reverse transcribed using the TaqmanRT system (Roche, Basel,
Switzerland). Real-time PCR analysis was performed on cDNA using QuantiTect
SYBR green PCR kit (Qiagen) on an ABI Prism 7900 (Applied Biosystems, Foster
City, CA, USA). Relative fold expression was determined using the comparative
threshold cycle method and β-actin. Primer sequences were as follows: c-myc
sense caaatcctgtacctcgtccgattc, antisense cttcttgctcttcttcagagtcgc; mnt sense
cagtccctgaagaggaagga, antisense ccggagcacacgatctatct; ornithine decarboxylase
sense gaccttgtgaggagctgctgat, antisense tggcagtcaaactcgtccttag; cdk4 sense
cagtcagtggtgccagagatggag, antisense cagcgagggtttctccaccaag; β-actin sense
tattggcaacgagcggttc, antisense ccatacccaagaaggaaggct.
Statistical analysis. Statistical comparisons were made using a two-tailed
Student’s t-test with Prism v7.0 software (GraphPad, San Diego, CA, USA). Data
are shown as means±S.E.M. with P-values o0.05 considered statistically
significant. Mouse survival analysis was carried out using GraphPad Prism (Version
7.0) and significance determined using log-rank (Mantel–Cox) test.
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